Rodin Therapeutics

Rodin Therapeutics, a biotechnology company applying insights of epigenetics to novel therapeutics for neurological disorders, announced its founding by Atlas Venture and Proteros biostructures. Rodin is founded based on its insight into key epigenetic modulators of CNS function, privileged access to Proteros' best-in-class structural biology capabilities, and a team with deep CNS drug development and company formation experience. Rodin secured financing from Atlas Venture and Johnson & Johnson Development Corporation (JJDC).

Rodin Therapeutics headquartered in United States, North America, operates in the Biotechnology, Health Care, Therapeutics sector. The company focuses on Biotechnology and has secured $2.7B in funding across 48 round(s). With a team of 11-50 employees, Rodin Therapeutics is actively contributing to advancements in Biotechnology. Their latest funding round, Seed Round - Rodin Therapeutics, raised $Unknown amount. Discover more about their projects, partnerships, and impact on our platform.